Z Squared Inc. quarterly report, Q1 FY2023

Coeptis Therapeutics Holdings, Inc. — Q1 2023 Form 10-Q

Entity note: The supplied filing is for Coeptis Therapeutics Holdings, Inc., not Z Squared Inc. It covers the three months ended March 31, 2023; financial statements are unaudited. The company reports as a pharmaceutical developer focused on developing and partnering around drug products and therapeutic technologies.

Financial results and position

MetricQ1 2023Q1 2022 / prior period
Revenue$0$0
Operating expenses$6.45 million$15.72 million
Operating loss$6.45 million$15.72 million
Net loss$7.87 million$19.18 million
Loss per share, basic and diluted$0.39$1.52
Cash used in operating activities$1.68 million$0.96 million
Cash and cash equivalents$2.11 million at March 31$3.79 million at December 31, 2022
Total assets$5.94 million$7.92 million at December 31, 2022
Total liabilities$4.66 million$3.11 million at December 31, 2022
Stockholders’ equity$1.29 million$4.80 million at December 31, 2022

No gross profit or margins are meaningful because the company recorded no revenue or cost of goods sold. Cash declined by $1.68 million during the quarter. Current assets were $2.28 million and current liabilities $1.98 million, leaving working capital of approximately $0.30 million. Notes payable totaled $1.65 million, including a $1.5 million convertible note disclosed as in default and a $150,000 SBA loan. Separately, warrant liabilities were $2.51 million.

Changes versus comparable periods

  • Operating expenses fell approximately 59% year over year, primarily due to lower professional-services costs related to equity transactions.
  • Net loss declined approximately 59%; however, operating cash use increased from $0.96 million to $1.68 million.
  • Q1 2023 included a $1.39 million noncash expense from increased fair value of warrant liabilities. This was a significant contributor to the difference between operating loss and net loss.
  • Cash decreased from $3.79 million at year-end 2022 to $2.11 million at quarter-end. The company reported no cash financing proceeds in Q1 2023.

Outlook, risks, and notable items

  • Management said it does not expect significant revenue for at least the next two years and expects to need additional financing through equity, debt, collaborations, or licensing. No quantified financial guidance was provided.
  • The filing states that the accumulated deficit was $73.61 million and that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Management’s financing plans are not assured of success.
  • Development priorities include CD38-GEAR-NK and CD38-Diagnostic programs with VyGen, and a University of Pittsburgh CAR-T technology license and research agreement. Management said it had shifted away from prioritizing CPT60621 development.
  • The $1.5 million Purple BioTech convertible note, bearing 5% interest and due on or before February 2023, was reported as in default as of March 2023. The balance sheet classifies $1.5 million of notes payable as current.
  • Disclosure controls and procedures were deemed ineffective as of March 31, 2023, due to material weaknesses, including inadequate segregation of duties. Management said remediation was ongoing.
  • The company reported no material litigation and no subsequent events requiring adjustment or disclosure. It issued shares and subscribed shares for services during the quarter and recorded stock-based compensation and warrants issued for services.

Important facts for investors to verify

  • Confirm the issuer: this filing identifies Coeptis Therapeutics Holdings, Inc., despite the request metadata naming Z Squared Inc.
  • Check the status, accrued interest, maturity, and enforcement or restructuring terms of the defaulted $1.5 million note, and the company’s plan to meet near-term cash needs.
  • Review the going-concern disclosure alongside the cash balance, operating cash burn, and absence of Q1 financing proceeds.
  • Assess potential dilution from outstanding warrants, newly granted options, and shares issued or subscribed for services; the filing describes several warrant classes and terms.
  • Track development milestones, collaboration terms, and funding requirements for the company’s pipeline; the filing provides no revenue timetable beyond stating significant revenue is not expected for at least two years.
  • Review progress remediating the material weaknesses in disclosure controls and internal control over financial reporting.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.